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Introduction
With emerging cases of adrenal suppression being
reported in pediatric patients, finding appropriate ster-
oid sparing agents is of clinical importance. Tiotropium
bromide (TB), a long-acting anticholinergic, has recently
been investigated in adults as a steroid-sparing agent in
asthma step-up therapy. We report the first case of tio-
tropium bromide (TB) used as a step-up steroid sparing
agent in an adolescent with adrenal suppression second-
ary to inhaled mometasone furoate (MF).
Case description
A sixteen-year-old female with asthma and allergic rhinitis
treated MF/formoterol fumarate 800/ 20 mcg per day in
addition to intranasal MF presented with increasing fatigue,
weight loss, nausea and striae. Extensive initial hospital
investigations were normal. An AM cortisol was reported
< 50 nmol/L (170-540). She was started on hydrocortisone
therapy and changed to ciclesonide 400 mcg, as well as
montelukast and formoterol. Her energy and weight
improved after initiation of replacement hydrocortisone
therapy. Despite using sublingual grass immunotherapy,
during grass pollen season the patient’s asthma control
worsened. Rather than increase the dose of inhaled corti-
costeroids, 18 mcg of daily TB was added for a therapeutic
trial. The patient experienced symptomatic improvement
with less nocturnal cough, normal exercise tolerance and
4% improvement in FEV1.
Discussion
There is a limited repertoire of steroid sparing agents
available for use in the pediatric asthma population. While
adrenal suppression due to inhaled corticosteroids is con-
sidered relatively uncommon, and prior MF-induced adre-
nal suppression has only been reported by the authors,
finding suitable alternatives to inhaled corticosteroids is
paramount in this population. Physicians may consider a
trial of TB in an attempt to decrease the dose of inhaled
corticosteroids in their pediatric patients to avoid adrenal
suppression.
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